Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (Nasdaq: NTLA) announced on May 1, 2026 that it granted inducement awards to 43 new employees under its 2024 Inducement Plan.
The awards are time-based RSUs totaling 208,850 shares, vesting one-third annually over three years, and were approved under Nasdaq Listing Rule 5635(c)(4) by the compensation committee.
Intellia Therapeutics (Nasdaq: NTLA) announced the pricing of an underwritten public offering of 16,744,187 common shares at $10.75 per share, with gross proceeds of approximately $180 million before underwriting discounts and expenses.
The company granted underwriters a 30-day option to buy up to 2,511,628 additional shares. Jefferies, Goldman Sachs and Citigroup are joint book-runners. The offering is subject to market and other conditions and is being made under an automatic shelf registration on Form S-3ASR.
Intellia (Nasdaq: NTLA) announced an underwritten public offering of $150 million of common stock, with a 30-day underwriter option to purchase up to an additional 15% of the shares. All offered shares are to be sold by Intellia.
The offering is being led by Jefferies, Goldman Sachs and Citigroup, is subject to market and other conditions, and will be made under an automatic shelf registration on Form S-3ASR (File No. 333-275740). A preliminary prospectus supplement will be filed with the SEC.
Intellia Therapeutics (NASDAQ: NTLA) reported positive topline Phase 3 HAELO results for one-time in vivo gene edit lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE).
In 80 patients, a single 50 mg infusion reduced attacks by 87% versus placebo over a six-month efficacy period (mean monthly attack rate 0.26 vs 2.10; p<0.0001), with 62% attack- and therapy-free in the lonvo-z arm. Favorable safety observed; no serious adverse events in lonvo-z arm as of data cutoff (Feb 10, 2026). Rolling BLA to FDA initiated; potential U.S. launch in H1 2027 if approved.
Intellia Therapeutics (Nasdaq: NTLA) initiated a rolling BLA submission to the FDA for lonvo-z (formerly NTLA-2002) as a one-time in vivo CRISPR treatment for hereditary angioedema (HAE).
Phase 3 HAELO met its primary and all key secondary endpoints, showing most patients were free from HAE attacks and ongoing therapy during the six-month primary period. Intellia expects to complete the BLA in the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027. Lonvo-z holds RMAT designation and participated in the FDA CMC pilot to help expedite review.
Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026. This is described as the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate.
The company will host a webcast at 8:00 a.m. ET on April 27, 2026 to discuss the topline results; a replay will be available for approximately 90 days.
Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan. The awards comprised 67,150 RSUs vesting one-third annually over three years and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
All equity vesting is conditioned on continued service through vesting dates; awards were granted outside stockholder-approved plans pursuant to the inducement plan adopted by the board in June 2024.
Intellia Therapeutics (Nasdaq: NTLA) announced on March 6, 2026 that it granted inducement awards to six new employees under its 2024 Inducement Plan.
The awards were time-based restricted stock units totaling 16,500 shares, with one-third vesting annually over three years, granted March 1, 2026 and approved under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) presented four posters at AAAAI 2026 on lonvoguran ziclumeran (lonvo-z; NTLA-2002) for hereditary angioedema (HAE). A pooled Phase 1/2 cohort (n=32) given a one-time 50 mg dose showed durable plasma kallikrein reductions and a mean monthly attack rate ≤0.2 through up to three years.
Key readouts: 96% mean reduction in HAE attacks versus baseline, 31/32 (97%) attack-free and LTP-free at data cutoff, and 86% of 28 patients with >6 months follow-up attack-free and LTP-free for >6 months. A patient survey (n=100) highlighted ongoing treatment burden.
Intellia Therapeutics (Nasdaq: NTLA) announced the FDA has lifted the clinical hold on the IND for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) in ATTR-CM, allowing enrollment to resume with enhanced safety measures.
Holds were originally placed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased bilirubin. Mitigations include intensified liver monitoring, short-term steroid guidance, new exclusion criteria (including ejection fraction <25% and recent cardiovascular instability), and exclusion for certain liver abnormalities. MAGNITUDE plans ~1,200 patients (2:1 randomization, single 55 mg infusion); MAGNITUDE-2 enrolls ~60 ATTRv-PN patients (1:1).